AI Score

Unlock

Viridian Therapeutics Inc... (VRDN)

AI Score

Unlock

14.40

-1.13 (-7.28%)

At close: Mar 03, 2025, 3:59 PM

14.41

0.03%

After-hours: Mar 03, 2025, 04:00 PM EST

No 1D chart data available

Bid	13.76
Market Cap	1.14B
Revenue (ttm)	360.17K
Net Income (ttm)	-306.6M
EPS (ttm)	-4.32
PE Ratio (ttm)	-3.33
Forward PE	-4.55
Analyst	Buy

Ask	15.34
Volume	963,062
Avg. Volume (20D)	1,339,525
Open	15.60
Previous Close	15.53
Day's Range	14.10 - 15.69
52-Week Range	11.40 - 27.20
Beta	1.35

About VRDN

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 18, 2014

Employees 94

Stock Exchange NASDAQ

Ticker Symbol VRDN

Website https://www.viridiantherapeutics.com

Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for VRDN stock is "Buy." The 12-month stock price forecast is $34, which is an increase of 136.03% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Earnings Surprise

Viridian Therapeutics has released their quartely earnings on Feb 27, 2025:

Revenue of $72K exceeds estimates by $23.23K, with 0.00% YoY growth.

EPS of -0.81 exceeds estimates by 0.19, with 16.49% YoY growth.

Next Earnings Release

Viridian Therapeutics Inc. is scheduled to release its earnings on May 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+20.67%

Viridian Therapeutics shares are trading higher af... Unlock content with Pro Subscription

5 months ago

+7.76%

Viridian Therapeutics shares are trading higher after BTIG raised its price target on the stock from $56 to $61.

News

1 day ago · seekingalpha.com

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window

Viridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive ...

4 days ago · zacks.com

Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to loss of $1.35 per share a year ago.

3 weeks ago · businesswire.com

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

2 months ago · seekingalpha.com

Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)

Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing...

2 months ago · seekingalpha.com

Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation

Viridian's veligrotug delivered positive data from two phase 3 trials in active and chronic TED patients. The results from the THRIVE-2 trial in chronic TED patients show hints of differentiation to T...

2 months ago · seekingalpha.com

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)

Viridian Therapeutics, Inc.'s stock surged over 20% after key trial results came out before the bell on Monday. The study results triggered a rash of buy reissuances from analyst firms and improved th...

2 months ago · investors.com

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

Viridian Therapeutics stock popped Monday after the company scored a win in thyroid eye disease, a condition that causes the eyes to swell. The post Viridian Therapeutics Skyrockets After Besting Amge...

2 months ago · reuters.com

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Viridian Therapeutics said on Monday its experimental drug to treat an immune system disorder, chronic thyroid eye disease, met the main goal of a late-stage study.

2 months ago · businesswire.com

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

2 months ago · businesswire.com

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024